Thor Halfdanarson, MD

Thor Halfdanarson, MD, outlines real-world challenges in radiopharmaceutical production and delivery and highlights key questions for upcoming trials, including alpha vs beta emitters and long-term toxicity.

Thor Halfdanarson, MD, discussed early results showing favorable response rates and manageable safety with ^212Pb-VMT-α-NET, along with the role of PET imaging in optimizing patient selection for future trials.

Oncologist Thor Halfdanarson reviews dose-finding data for the targeted α radioligand therapy [^212Pb]VMT- α-NET, highlighting manageable toxicity, stable renal function, and plans for phase 2 evaluation.